Alaya bio

Discover the future of cancer treatment with Alaya. Despite major progress in oncology, too many cancers remain resistant and relapse rates are often high. Immunotherapy has changed the paradigm, and CAR-T cell therapies—engineered immune cells able to target and destroy tumors—have demonstrated breakthrough efficacy, especially in blood cancers.

Alaya is pioneering a next-generation, off-the-shelf CAR-T therapy leveraging an advanced polymeric platform. This approach addresses long-standing challenges faced by existing CAR-Ts and is backed by robust preclinical data. The first application targets immuno-oncology, aiming to improve outcomes for patients where current treatments fall short.

Alaya’s leadership team includes Renaud Vaillant and Cécile Bauche—recognized serial entrepreneurs in cell and gene therapy, joined by Dr Michel Sadelain, world-renowned CAR-T expert and Key Opinion Leader.

Join us on our mission to transform cancer care!